Sort
10,766 grants matching “checkpoint inhibitor”
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
$474,721Judith S Leopold · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Lung Resident Mesenchymal Cells in the Pre-Metastatic Niche Formation
$474,621Guangwen Ren · Jackson Laboratory · R01 · FY2023 · CA
Lung Resident Mesenchymal Cells in the Pre-Metastatic Niche Formation
$474,620Guangwen Ren · Jackson Laboratory · R01 · FY2022 · CA
Defining and Targeting Homologous Recombination Deficiency in Breast Cancer
$474,520Simon N Powell · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA
Targeting Autophagy in Hereditary Breast Cancer
$474,468Bing Xia · Rbhs -Cancer Institute Of New Jersey · R01 · FY2017 · CA
Targeting Autophagy in Hereditary Breast Cancer
$474,468Bing Xia · Rbhs -Cancer Institute Of New Jersey · R01 · FY2016 · CA
Novel roles for the DNA damage response kinase CHK1 in TCR/ITAM signaling
$474,449Carrie L. Lucas · Yale University · R01 · FY2018 · AI
Elucidating mechanisms underlying replication checkpoint control
$474,447Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
$474,357Paolo Casali · University Of Texas Hlth Science Center · R01 · FY2021 · AI
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
$474,357Paolo Casali · University Of Texas Hlth Science Center · R01 · FY2020 · AI
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
$474,356Paolo Casali · University Of Texas Hlth Science Center · R01 · FY2023 · AI
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1
$474,356Paolo Casali · University Of Texas Hlth Science Center · R01 · FY2022 · AI
Targeting lymph node metastases to block cancer progression
$474,295Timothy P Padera · Massachusetts General Hospital · R01 · FY2024 · CA
Systematic, molecular level analysis of the Fc receptor ligation on antibody effector functions
$474,247George Georgiou Georgiou · University Of Texas At Austin · U01 · FY2020 · AI
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.
$474,236Alexander H. Stegh · Washington University · R01 · FY2024 · NS
Targeting Posttranslational Modifications in Breast Carcinogenesis
$474,218Yong Wan · Northwestern University At Chicago · R01 · FY2021 · CA
AHR-mediated immunosuppression in glioblastoma
$474,075Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2022 · ES
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
$474,043Ralph P Mason · Ut Southwestern Medical Center · R01 · FY2021 · CA
Intrapleural immunotherapeutic nanoparticles for MPE treatment
$473,950Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2021 · CA
Mechanisms and Functions of ATR signaling
$473,947David K Cortez · Vanderbilt University · R01 · FY2020 · CA
Mechanisms and Functions of ATR signaling
$473,947David K Cortez · Vanderbilt University · R01 · FY2021 · CA
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
$473,881Josep M Llovet · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Targeting UHRF1 in combinational immunotherapy
$473,749Xiao-Fan Wang · Duke University · R01 · FY2019 · CA
A modular cell therapy platform for controlling immunological tolerance
$473,726Nathan Edward Reticker-Flynn · Stanford University · DP2 · FY2023 · AI
Molecular Biology of Pediatric Tumors
$473,711Lee J. Helman · Division Of Clinical Sciences - Nci · ZIA · FY2010 · CA